CN117899159A - Medicine for treating bone marrow depression after chemotherapy and preparation method thereof - Google Patents
Medicine for treating bone marrow depression after chemotherapy and preparation method thereof Download PDFInfo
- Publication number
- CN117899159A CN117899159A CN202311778520.0A CN202311778520A CN117899159A CN 117899159 A CN117899159 A CN 117899159A CN 202311778520 A CN202311778520 A CN 202311778520A CN 117899159 A CN117899159 A CN 117899159A
- Authority
- CN
- China
- Prior art keywords
- parts
- bone marrow
- chemotherapy
- blood
- marrow depression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 60
- 238000002512 chemotherapy Methods 0.000 title claims abstract description 47
- 206010065553 Bone marrow failure Diseases 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 229940079593 drug Drugs 0.000 title description 16
- 238000011282 treatment Methods 0.000 claims abstract description 41
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 17
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 17
- 241000893536 Epimedium Species 0.000 claims abstract description 16
- 108010010803 Gelatin Proteins 0.000 claims abstract description 16
- 235000018905 epimedium Nutrition 0.000 claims abstract description 16
- 229920000159 gelatin Polymers 0.000 claims abstract description 16
- 239000008273 gelatin Substances 0.000 claims abstract description 16
- 235000019322 gelatine Nutrition 0.000 claims abstract description 16
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 16
- 235000001287 Guettarda speciosa Nutrition 0.000 claims abstract description 15
- 241000123069 Ocyurus chrysurus Species 0.000 claims abstract description 15
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 15
- 241000234276 Curculigo Species 0.000 claims abstract description 14
- 244000153955 Reynoutria sachalinensis Species 0.000 claims abstract description 14
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 claims abstract description 14
- 235000011477 liquorice Nutrition 0.000 claims abstract description 14
- 239000011324 bead Substances 0.000 claims abstract description 13
- 244000241463 Cullen corylifolium Species 0.000 claims abstract description 9
- 229940107666 astragalus root Drugs 0.000 claims abstract description 9
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 9
- 244000061520 Angelica archangelica Species 0.000 claims abstract 5
- 239000000463 material Substances 0.000 claims description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 13
- 239000000284 extract Substances 0.000 claims description 11
- 235000006533 astragalus Nutrition 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 241001061264 Astragalus Species 0.000 claims description 6
- 210000004233 talus Anatomy 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 5
- 238000005303 weighing Methods 0.000 claims description 5
- 240000001341 Reynoutria japonica Species 0.000 claims description 4
- 235000018167 Reynoutria japonica Nutrition 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 244000269722 Thea sinensis Species 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 abstract description 58
- 239000008280 blood Substances 0.000 abstract description 58
- 230000000694 effects Effects 0.000 abstract description 26
- 210000003734 kidney Anatomy 0.000 abstract description 19
- 230000000740 bleeding effect Effects 0.000 abstract description 9
- 238000001816 cooling Methods 0.000 abstract description 6
- 230000008093 supporting effect Effects 0.000 abstract description 4
- 230000004821 effect on bone Effects 0.000 abstract description 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 210000001185 bone marrow Anatomy 0.000 description 25
- 230000001629 suppression Effects 0.000 description 23
- 208000024891 symptom Diseases 0.000 description 14
- 239000000686 essence Substances 0.000 description 13
- 210000000952 spleen Anatomy 0.000 description 12
- 210000004185 liver Anatomy 0.000 description 11
- 241000125175 Angelica Species 0.000 description 10
- 208000032843 Hemorrhage Diseases 0.000 description 9
- 210000001772 blood platelet Anatomy 0.000 description 9
- 210000000265 leukocyte Anatomy 0.000 description 9
- 206010067484 Adverse reaction Diseases 0.000 description 8
- 230000006838 adverse reaction Effects 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 7
- 230000007812 deficiency Effects 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 102000001554 Hemoglobins Human genes 0.000 description 6
- 108010054147 Hemoglobins Proteins 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 6
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 210000000440 neutrophil Anatomy 0.000 description 6
- 238000010298 pulverizing process Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 238000001959 radiotherapy Methods 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 230000003394 haemopoietic effect Effects 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 241000382455 Angelica sinensis Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241000217407 Margaritifera Species 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000003995 blood forming stem cell Anatomy 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- 238000007873 sieving Methods 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 241000045403 Astragalus propinquus Species 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 2
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 229940010454 licorice Drugs 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 208000013220 shortness of breath Diseases 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 244000084791 Curculigo orchioides Species 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108010092408 Eosinophil Peroxidase Proteins 0.000 description 1
- 102100031939 Erythropoietin Human genes 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 1
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 description 1
- 101000799461 Homo sapiens Thrombopoietin Proteins 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033546 Pallor Diseases 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 102100034195 Thrombopoietin Human genes 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 231100001018 bone marrow damage Toxicity 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 190000008236 carboplatin Chemical compound 0.000 description 1
- 210000004970 cd4 cell Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 208000024389 cytopenia Diseases 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 102000044890 human EPO Human genes 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/487—Psoralea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Medicines Containing Plant Substances (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Abstract
The invention discloses a medicament for treating bone marrow depression after chemotherapy and a preparation method thereof, relating to the field of traditional Chinese medicines, and the technical scheme is as follows: comprises 30 to 80 parts of astragalus root, 10 to 60 parts of angelica, 15 to 40 parts of malaytea scurfpea fruit, 15 to 40 parts of madder root, 15 to 40 parts of giant knotweed, 10 to 40 parts of curculigo rhizome, 20 to 50 parts of epimedium herb, 10 to 30 parts of donkey-hide gelatin bead, and 10 to 20 parts of liquorice. The invention has multiple treatment effects of tonifying qi and blood, clearing heat and cooling blood, removing blood stasis and stopping bleeding, tonifying kidney and supporting yang, tonifying essence and blood and the like, thereby having positive treatment effect on bone marrow depression after chemotherapy.
Description
Technical Field
The invention relates to the field of traditional Chinese medicines, in particular to a medicine for treating bone marrow depression after chemotherapy and a preparation method thereof.
Background
Bone marrow suppression is one of the common adverse reactions after chemotherapy, and is mainly expressed by 'peripheral blood leucocyte, even whole blood cytopenia', or symptoms such as anemia, hemorrhage and the like occur, even serious infection is caused, so that the patient cannot complete subsequent treatment. On the one hand, chemotherapy is one of the most effective means for treating malignant tumor in the current world, on the other hand, it causes bone marrow suppression while killing malignant tumor cells, and light people influence subsequent treatment, and serious people may die due to complications caused by the follow-up treatment, so that the prevention and treatment of bone marrow suppression after chemotherapy is a key for ensuring the continuous progress of chemotherapy and improving clinical curative effect.
Modern medicine considers bone marrow suppression to be divided into two categories, acute and chronic. Most chemotherapeutic agents, such as alkylating agents, pyrimidine analogs, anthracyclines, nitroureas, methotrexate, etc., are highly toxic to bone marrow, leading to the development of acute myelosuppression by causing the attenuation of hematopoietic progenitor cells (hematopoieticprogenitorcells, HPCs). Acute myelosuppression usually occurs shortly after chemotherapy, and our body can promote hematopoietic recovery by the application of Hematopoietic Growth Factors (HGFs). However, if a chemotherapeutic regimen is selected with drugs such as carboplatin, busulfan, etc., that are highly selective for hematopoietic stem cells (hematopoieticstemcells, HSCs), chronic bone marrow damage occurs as a result of depletion of HPCs and a concomitant decrease in HSCs reserves and self-renewal capacity. It is currently believed that the pathogenesis of bone marrow suppression caused by chemotherapy is mainly related to aging, apoptosis, and damage of the hematopoietic microenvironment of the bone marrow by multipotent hematopoietic stem cells (hematopoieticstemcell, HSCs).
In Western medicine, at present, leucocyte rising, anemia correcting and platelet rising treatment are adopted, and transfusion treatment is carried out if necessary, but clinical patients often react, bone or muscle pain occurs after using a leucocyte rising needle, leucocytes cannot be quickly raised without injection, and the subsequent treatment time is prolonged. In the long-term treatment process of traditional Chinese medicine, abundant clinical experience is accumulated, and a better curative effect is obtained. The traditional Chinese medicine considers that the bone marrow suppression can be classified into the categories of consumptive disease and blood deficiency. "Lingqiao Ji. Qi-releasing" carries: the middle energizer is qi-affected to collect juice, and changes into red, which is called blood. "Nei Jing" suggests the theory of kidney governing bone and marrow generation. For the theory of disease sources: essence and blood. The kidney essence is full, the bone marrow is sufficient, and qi and blood can be produced. Kidneys are congenital origin, spleen and stomach are acquired origin, kidneys govern bone marrow production, store essence, spleen and stomach are sources of qi and blood biochemistry, and food essence transformed by spleen and stomach is a main substance of transforming into blood; liver stores blood, essence can produce blood, essence and blood are mutually generated, and qi and blood are basic substances of vital activities of human bodies, so that power is provided for the human bodies.
Zhang Huahao and other discussion systems evaluate the relevant curative effects of the eight-treasure soup on preventing and treating bone marrow suppression caused by radiotherapy and chemotherapy of tumors, and the eight-treasure soup is mined to effectively reduce the occurrence of bone marrow suppression of patients, improve the recent treatment effect of tumors, relieve the WBC, NEU, PLT injury level caused by radiotherapy and chemotherapy, and also improve the CD3 and CD4 cell level of the immune function of the patients. Wang Hongjun and the like are used for treating marrow suppression after lung squamous cancer chemotherapy by combining moxibustion with flavored yang-raising stomach-benefiting decoction, and the result proves that the lung squamous cancer chemotherapy marrow suppression condition can be improved, the immune function is improved, and the adverse reaction is small.
Therefore, the invention provides a medicament for treating bone marrow depression after chemotherapy and a preparation method thereof, which have important practical significance.
Disclosure of Invention
The invention aims to provide a medicament for treating bone marrow depression after chemotherapy, which mainly has the effects of tonifying qi, nourishing blood and the like.
The technical aim of the invention is realized by the following technical scheme: the medicine for treating bone marrow depression after chemotherapy includes astragalus root 30-80 weight portions, angelica 10-60 weight portions, malaytea scurfpea fruit 15-40 weight portions, madder root 15-40 weight portions, giant knotweed 15-40 weight portions, curculigo rhizome 10-40 weight portions, epimedium 20-50 weight portions, ass hide gelatin 10-30 weight portions and licorice 10-20 weight portions.
Preferably, the present invention is further configured to: comprises 30 parts of astragalus root, 10 parts of angelica, 15 parts of malaytea scurfpea fruit, 15 parts of madder root, 15 parts of giant knotweed, 10 parts of curculigo rhizome, 20 parts of epimedium herb, 10 parts of donkey-hide gelatin bead and 10 parts of liquorice.
Preferably, the present invention is further configured to: comprises 50 parts of astragalus root, 30 parts of angelica, 20 parts of malaytea scurfpea fruit, 20 parts of madder root, 20 parts of giant knotweed, 20 parts of curculigo rhizome, 30 parts of epimedium herb, 20 parts of donkey-hide gelatin bead and 15 parts of liquorice.
Preferably, the present invention is further configured to: comprises 80 parts of astragalus root, 60 parts of angelica, 40 parts of fructus psoraleae, 40 parts of madder, 40 parts of giant knotweed, 40 parts of curculigo rhizome, 50 parts of epimedium herb, 30 parts of donkey-hide gelatin bead and 20 parts of liquorice.
Another object of the present invention is to provide a method for preparing a medicament for treating bone marrow depression after chemotherapy. The method specifically comprises the following steps:
s1: weighing each component and the pharmaceutic adjuvant according to the formula amount of claim 1, wherein the pharmaceutic adjuvant is crushed and then screened, and the other medicinal materials are crushed into coarse powder;
s2: mixing the medicinal materials obtained in the step S1, and decocting the medicinal materials for a plurality of times;
S3: and (3) filtering and combining the decoction obtained in each time of decoction in the step (S2) in sequence to obtain the medicament for treating the bone marrow depression after chemotherapy.
Preferably, the present invention is further configured to: the times of decocting the medicinal materials in the step S2 are 3 times, wherein the first time is 3 hours by 12 times of water, the second time is 2 hours by 8 times of water, and the third time is 0.5 hour by 6 times of water.
Preferably, the present invention is further configured to: the medicine obtained in the step S3 is one of a soft extract, a capsule, a granule, an oral liquid, a tablet, a pill, a tea, a water decoction or a powder formulation.
The pharmacology of the medicine of the invention is as follows:
radix astragali: sweet, slightly warm, enter spleen and lung meridians, tonify qi and raise yang, benefit defensive qi and strengthen superficies, induce diuresis to alleviate edema, promote sore and promote granulation;
Chinese angelica root: sweet, warm, enter liver and spleen meridians, activate blood, enrich blood, regulate menstruation, relieve pain, tranquilize and calm, protect liver;
fructus psoraleae: bitter, warm, enter lung, spleen and kidney meridians, tonify bones, nourish yin and moisten dryness, tonify spleen and stomach, strengthen kidney and strengthen yang, resist inflammation and stop bleeding;
Radix Rubiae: bitter, slightly cold, heart, liver and large intestine channels, clearing heat and detoxicating, cooling blood and stopping bleeding, activating blood and dissolving stasis, protecting liver and nourishing liver, resisting oxidation and resisting tumor;
giant knotweed rhizome: pungent, bitter and warm, enter liver and spleen meridians, detoxify and reduce swelling, clear heat and cool blood, warm uterus and dredge collaterals, nourish liver and tranquilize;
Curculigo rhizome: bitter, sweet, flat, and good for heart, liver and kidney meridians, clearing away heat and toxic materials, promoting diuresis, soothing liver, regulating qi, nourishing kidney and strengthening yang;
epimedium herb: sweet, pungent and warm, has the effects of invigorating kidney meridian, tonifying kidney and yang, warming kidney and tonifying yang, replenishing vital essence and qi, strengthening kidney and securing essence, and resisting inflammation, oxidation and tumor;
Donkey-hide gelatin: sweet and flat, and has the functions of nourishing yin, moistening dryness, nourishing blood, tonifying deficiency, promoting blood circulation, removing blood stasis, nourishing liver and improving eyesight;
Licorice root: sweet and flat, enters spleen, lung and heart meridian, warms middle energizer and arrest vomiting, supplements spleen and replenishing qi, moistens lung and relieves cough;
The treatment mechanism of the invention is as follows:
Astragalus and angelica are monarch drugs, and have the effects of tonifying qi and blood, cooling blood and stopping bleeding and removing blood stasis;
astragalus mongholicus and angelica are principal drugs of the recipe and have the efficacy of tonifying qi and enriching blood. Astragalus has the effects of improving immunity, enhancing body resistance and promoting blood generation; the angelica is rich in vitamins A, B and iron, can stimulate the generation of red blood cells, and has remarkable blood replenishing effect; thus, the condition of low hematopoietic function after chemotherapy can be improved, and the degree of bone marrow suppression is reduced;
giant knotweed rhizome removes blood stasis, and combines the effect of filling up and removing blood stasis of madder, namely 'old blood is not removed, new blood is not generated, and new blood is daily generated' is taken as a ministerial drug;
The madder and the giant knotweed are ministerial drugs of the recipe and have the characteristics of clearing heat, cooling blood, removing blood stasis and stopping bleeding. Radix Rubiae is rich in flavonoids, and has effects of clearing heat, removing toxic substances, cooling blood and stopping bleeding; the giant knotweed contains multilayer inoculation sterone substances, can promote blood circulation to remove blood stasis, and has certain help to treat the heat toxin symptoms and bleeding problems possibly occurring after chemotherapy; thus being beneficial to improving blood circulation, reducing inflammatory reaction, promoting blood purification and generating blood platelets;
donkey-hide gelatin bead has effects of replenishing blood and stopping bleeding; fructus Psoraleae, rhizoma Curculiginis, and herba Epimedii are used as adjuvant drugs for invigorating kidney, supporting yang, and replenishing essence and blood;
fructus Psoraleae, rhizoma Curculiginis and herba Epimedii are adjuvant drugs of the recipe, and have effects of invigorating kidney, supporting yang, and replenishing essence and blood. The chemotherapy often causes the conditions of kidney deficiency, yang deficiency, essence deficiency and the like, and the fructus psoraleae, the rhizoma curculiginis and the epimedium are all medicinal materials with kidney tonifying functions in the traditional Chinese medicine. They can promote the recovery of kidney function, increase the generation of yang qi, and supplement essence and blood, thereby improving the immunity and blood generation of the organism;
the liquorice is mainly used for regulating the functions of the medicines, and the whole formula has the effects of strengthening the spleen, tonifying the kidney, supplementing qi and nourishing blood;
glycyrrhrizae radix is the guiding drug of the recipe and has the function of harmonizing drug property. The liquorice contains glycyrrhizin and other components, has mild properties, can harmonize the properties of other medicinal materials, and enhances the overall effect of the prescription; the licorice also has the effects of invigorating spleen and replenishing qi, can increase the synthesis and absorption of human energy, and can improve the metabolism and immune function of the organism.
The medicine of the invention mainly treats: deficiency of both qi and blood; the symptoms are white and lusterless complexion or sallow complexion, pale lips and nails, palpitation, shortness of breath, listlessness, anorexia, dizziness, pale and fat tongue with white coating, weak pulse and has the effects of tonifying qi and nourishing blood.
In summary, the invention has the following beneficial effects:
1. The medicine formula of the invention mainly comprises the combination of medicines such as astragalus, angelica, madder, giant knotweed, donkey-hide gelatin bead, malaytea scurfpea fruit, curculigo rhizome, epimedium herb, liquorice and the like, and has multiple treatment effects of tonifying qi and blood, clearing heat and cooling blood, removing blood stasis and stopping bleeding, tonifying kidney and supporting yang, and tonifying essence and blood and the like, thereby having positive treatment effect on bone marrow depression after chemotherapy;
2. The invention adopts a method of multiple times of decoction to fully extract the effective components in the medicinal materials, ensures the concentration and quality of the medicinal materials, prepares different dosage forms such as extractum and granules, is convenient for patients to use and take, and achieves the effects of balancing and promoting the compatibility of the medicinal materials according to the characteristics of the nature and the taste of the medicinal materials.
Detailed Description
The invention is described in further detail below in connection with examples and clinical data.
Example 1: the medicine for treating bone marrow depression after chemotherapy comprises medicinal materials and pharmaceutic adjuvant, and is prepared from the following raw materials in parts by weight: 30 parts of astragalus membranaceus, 10 parts of angelica sinensis, 15 parts of fructus psoraleae, 15 parts of radix rubiae, 15 parts of polygonum cuspidatum, 10 parts of curculigo orchioides, 20 parts of epimedium herb, 10 parts of donkey-hide gelatin beads and 10 parts of liquorice.
The preparation method of the granule of the medicine comprises the following steps:
s1: weighing the medicinal materials according to the prescription, pulverizing Concha Margaritifera, sieving with 200 mesh sieve, and pulverizing other medicinal materials into coarse powder;
s2: mixing all the above materials, decocting with 12 times of water for 3 hr, decocting with 8 times of water for 2 hr, and decocting with 6 times of water for 0.5 hr;
S3: filtering, and combining the decoctions obtained in the step S2;
s4: concentrating the decoction in S3 to obtain extract with relative density of 1.10-1.15 at 80deg.C;
s5: adding 4 times of sucrose powder according to the weight of the extract in the step S4;
S6: mixing, granulating, oven drying, and grading to obtain granule.
The administration method comprises the following steps: it is administered by soaking in boiled water 10g at a time and 3 times daily.
Example 2: the medicine for treating bone marrow depression after chemotherapy comprises medicinal materials and pharmaceutic adjuvant, and is prepared from the following raw materials in parts by weight: 50 parts of astragalus, 30 parts of angelica, 20 parts of fructus psoraleae, 20 parts of madder, 20 parts of polygonum cuspidatum, 20 parts of curculigo, 30 parts of epimedium, 20 parts of donkey-hide gelatin beads and 15 parts of liquorice.
The preparation method of the decoction of the medicine comprises the following steps:
s1: weighing the medicinal materials according to the prescription, pulverizing Concha Margaritifera, sieving with 200 mesh sieve, and pulverizing other medicinal materials into coarse powder;
s2: mixing all the above materials, decocting with 12 times of water for 3 hr, decocting with 8 times of water for 2 hr, and decocting with 6 times of water for 0.5 hr;
S3: filtering, and combining the decoctions obtained in the step S2;
S4: concentrating the decoction in S3 to obtain extract with relative density of 1.10-1.15 at 60-65deg.C;
S5: adding 100g of honey into the extract in the step S4, and heating and uniformly mixing;
S6: concentrating the extract obtained in step S5 to obtain extract with relative density of 1.2-1.25 at 60-65deg.C.
The administration method comprises the following steps: orally administered, 15g each time before and after meals, after dissolving in hot water; can also be directly swallowed.
Example 3: the medicine for treating bone marrow depression after chemotherapy comprises medicinal materials and pharmaceutic adjuvant, and is prepared from the following raw materials in parts by weight: 80 parts of astragalus, 60 parts of angelica, 40 parts of fructus psoraleae, 40 parts of madder, 40 parts of polygonum cuspidatum, 40 parts of curculigo, 50 parts of epimedium, 30 parts of donkey-hide gelatin beads and 20 parts of liquorice.
The preparation method of the capsule of the medicine comprises the following steps:
s1: weighing the medicinal materials according to the prescription, pulverizing Concha Margaritifera, sieving with 200 mesh sieve, and pulverizing other medicinal materials into coarse powder;
s2: mixing all the above materials, decocting with 12 times of water for 3 hr, decocting with 8 times of water for 2 hr, and decocting with 6 times of water for 0.5 hr;
S3: filtering, and combining the decoctions obtained in the step S2;
s4: concentrating the decoction in S3 to obtain extract with relative density of 1.10-1.15 at 80deg.C;
s5: drying the extractum in S4 at 70 ℃ under reduced pressure to obtain dry extractum, and crushing;
s6: adding 10% starch into the dry extract obtained in the step S5, uniformly mixing, and granulating with 70% ethanol;
S7: and (3) drying the particles in the step S6, and finishing the particles to obtain the capsule.
The administration method comprises the following steps: it is orally administered 3 granules at a time, 3 times a day.
Clinical trial example 1:
clinical observations of the invention for treating chemotherapy bone marrow suppression
1. Case origin:
Case sources are malignant tumor patients who meet inclusion criteria in a first affiliated hospital of Guizhou university of traditional Chinese medicine, 7 months 2017 to 1 month, and who receive chemotherapy, bone marrow suppression occurs after chemotherapy. The clinical trial was finally performed in 60 patients, 30 controls and 30 experiments. Group 15 men and 15 women were observed. Age 38-71 years, average age (54.52 + -8.26) years; 14 men and 16 women in the control group; age 40-70 years, average age (55.03+ -7.52) years. The medicine is taken 48h after the end of the chemotherapy in the period, and the medicine is continuously taken for 7d in 1 treatment course. The general data for the two groups of patients were comparable with no statistical difference (P > 0.05). The patients were evaluated for improvement in bone marrow suppression, improvement in symptoms, and incidence of adverse reactions after the end of both groups of treatments using World Health Organization (WHO) standards (see table 1).
Table 1 graduation of bone marrow suppression after chemotherapy
| 0 | 1 | 2 | 3 | 4 | |
| Hemoglobin (g/L) | ≥110 | 109-95 | 94-80 | 79-65 | <65 |
| White blood cells (10 9/L) | ≥4.0 | 3.9-3.0 | 2.9-2.0 | 1.9-1.0 | <1.0 |
| Granulocytes (10 9/L) | ≥2.0 | 1.9-1.5 | 1.4-1.0 | 0.9-0.5 | <0.5 |
| Blood platelet (10 9/L) | ≥100 | 99-75 | 74-50 | 49-25 | <25 |
2. Diagnostic criteria:
(1) The malignant tumor is identified by imaging and pathological diagnosis, bone marrow suppression appears after chemotherapy, and blood related examination is identified;
(2) After chemotherapy, the leucocyte is < 4.0X10 9/L, the haemoglobin is <110g/L, and the platelet is used for treating the leucocyte
<100×10 9/L or neutrophil <2×10 9/L.
3. The treatment method comprises the following steps:
Control group: recombinant human erythropoietin injection (CHO cells) was administered according to the patient' S condition (Hayaku group bioengineering Co., ltd., approval document: national drug standard S20073009, specification: 6000 IU); polyethylene glycol recombinant human granulocyte stimulating factor injection [ Qilu pharmaceutical Co., ltd., approval document: chinese medicine standard words S20150013, specification 1.35X10 8 IU (3.0 mg): 1.0mL ]; recombinant human thrombopoietin injection (Shenyang Sansheng pharmaceutical Co., ltd., approval of the literature: national drug standard S20050048, specification: 15000U/1 mL) for treatment. EPO dosage: the injection is subcutaneously injected for 150U/kg, and iron agent, vitamin B12, folic acid and the like are simultaneously taken for 3 times/week, and the medicine stopping is based on the hemoglobin level of >80g/L or the hematocrit of >40%.
PEGrhG-CSF usage amount: 100g/kg, 48h after the end of the administration of the antitumor drug in each chemotherapy cycle, based on the continuous detection of neutrophils with absolute value >10×10 9/L or total leukocytes >10×10 9/L twice.
TPO usage amount: subcutaneous injection 15000U/d,7d for 1 treatment cycle, and drug withdrawal based on platelet count > 50X 10 9/L. Observation group: according to the syndrome of the patient, the self-made qi-tonifying and blood-nourishing prescription (astragalus root 30 Chinese angelica, malaytea scurfpea fruit 10, india madder root 15 giant knotweed rhizome 15 curculigo rhizome 10 epimedium herb 20 donkey-hide gelatin 10 liquoric root 10) is treated.
4. Efficacy scoring criteria and observations:
(1) Two groups of Chinese medicine syndromes are integrated: according to the severity of symptoms, the symptoms are divided into asymptomatic, mild, moderate and severe, which are respectively 0-3 minutes, the symptoms are recorded as 0-9 minutes, the tongue coating is 0-3 minutes, and the pulse condition is 0-3 minutes. Each evaluation was performed 1 time before the start of the treatment and after the end of the treatment.
(2) Two sets of peripheral blood related indicators: all patients were collected on morning fasting venous blood at 3d intervals before and after initiation of treatment, and the number of leukocytes, neutrophils, and platelets in the blood was measured, and hemoglobin levels in the blood were measured using a beckmann kurt IMMAGE specific protein analyzer.
(3) Two groups of adverse reactions occur.
5. Statistics are carried out according to the curative effect evaluation standards, and clinical study results of the group-entering cases are shown in the following table:
Table 2 myelosuppression index comparison
| Group of | Number of examples | 0 Degree | I degree | Degree II | III degree |
| Observation group | 30 | 9 | 12* | 7* | 2* |
| Control group | 30 | 4 | 16 | 6 | 4 |
After treatment, the improvement of the bone marrow suppression degree of the observed group is superior to that of the control group, and the comparison difference between the treatment effect groups has statistical significance (P is less than 0.05).
Table 3 comparison of Chinese medicine symptoms score before and after treatment
After treatment, the traditional Chinese medicine syndrome score of the observed group is obviously lower than that of the control group, and the comparison difference between the treatment effect groups has statistical significance (P is less than 0.05).
TABLE 4 comparison of peripheral blood related indicators before and after treatment
After treatment, the white blood cells, neutrophils, platelets and hemoglobin were observed to be higher on average than the control, and the differences between the treatment effect groups were statistically significant (P < 0.05).
TABLE 5 adverse reaction comparison
| Group of | Number of examples | Heating up | Debilitation | Gastrointestinal tract reaction | Alopecia | Incidence of complications (%) |
| Observation group | 30 | 1 | 3 | 2 | 3 | 30 |
| Control group | 30 | 1 | 9 | 2 | 5 | 56 |
After treatment, the incidence of adverse reactions in the observed group is significantly lower than that in the control group, and the comparison difference between the treatment effect groups is statistically significant (P < 0.05).
6. Conclusion of efficacy evaluation:
According to clinical trial researches on prevention and treatment of bone marrow suppression caused by radiotherapy and chemotherapy by using the medicine disclosed by the invention, the medicine disclosed by the invention can be used for well preventing and treating bone marrow suppression caused by radiotherapy and chemotherapy, wherein the improvement degree of bone marrow suppression of a patient is remarkable, the improvement case of light bone marrow suppression is improved by 100%, and the improvement case of severe bone marrow suppression is reduced by 50%; the scoring symptoms, tongue coating and pulse condition of the traditional Chinese medicine symptoms are obviously lower than those of a control group, wherein the symptom score is obviously reduced; white blood cells, neutrophils, platelet numbers, and hemoglobin levels were higher on average than the control group, with significant increases in hemoglobin, neutrophils, platelet numbers; the incidence rate of adverse reaction in the observation group is obviously lower than that of the adverse reaction in the control group by 30 percent;
Therefore, the self-fitting qi-tonifying blood-nourishing formula can effectively improve the bone marrow suppression degree of a patient after chemotherapy of malignant tumors, improve the traditional Chinese medicine symptoms of the patient, improve the blood cell level, has better safety and is worthy of further clinical popularization.
The following are cases related to the use of the drug of the present invention.
Case 1: wang Mouhua women, 45 years old, have no business. 2+ months after cervical cancer comprehensive treatment, and 1 week after debilitation. The patient is diagnosed with cervical squamous carcinoma in 2023 and 4 months, the period IB3 is considered in perfecting the related examination, the cisplatin synchronous radiotherapy and chemotherapy treatment is combined with the short-distance radiation treatment, the short-distance radiation treatment is completed for 2 months before the patient is finished, and the patient is hypodynamia before 1 week, so that the diagnosis and the treatment of the cervical squamous carcinoma in traditional Chinese medicine are required. The symptoms are as follows: lassitude, shortness of breath, lazy speaking, insomnia, amnesia, palpitation, fever, cough, abdominal pain, diarrhea, frequent urination, pain in urination, and rotation of the blind. A pale-red tongue with little coating and a thready and rapid pulse. Auxiliary inspection: blood routine examination prompts: WBC 1.92×10-9/L, hb 76g/L, clinic dialectical "consumptive disease (deficiency of both qi and blood, deficiency of liver-yin and kidney-yin)", patient feel debilitating symptom improvement is obvious after taking granule of the example 1 for 2 treatment courses, review blood routine shows: WBC 4.2X10-9/L, hb 96g/L.
The present embodiment is only for explanation of the present invention and is not to be construed as limiting the present invention, and modifications to the present embodiment, which may not creatively contribute to the present invention as required by those skilled in the art after reading the present specification, are all protected by patent laws within the scope of claims of the present invention.
Claims (7)
1. A medicament for treating bone marrow depression after chemotherapy, which is characterized in that: comprises 30 to 80 parts of astragalus root, 10 to 60 parts of angelica, 15 to 40 parts of malaytea scurfpea fruit, 15 to 40 parts of madder root, 15 to 40 parts of giant knotweed, 10 to 40 parts of curculigo rhizome, 20 to 50 parts of epimedium herb, 10 to 30 parts of donkey-hide gelatin bead, and 10 to 20 parts of liquorice.
2. A medicament for the treatment of post-chemotherapy bone marrow depression according to claim 1, characterized in that: comprises 30 parts of astragalus root, 10 parts of angelica, 15 parts of malaytea scurfpea fruit, 15 parts of madder root, 15 parts of giant knotweed, 10 parts of curculigo rhizome, 20 parts of epimedium herb, 10 parts of donkey-hide gelatin bead and 10 parts of liquorice.
3. A medicament for the treatment of post-chemotherapy bone marrow depression according to claim 1, characterized in that: comprises 50 parts of astragalus root, 30 parts of angelica, 20 parts of malaytea scurfpea fruit, 20 parts of madder root, 20 parts of giant knotweed, 20 parts of curculigo rhizome, 30 parts of epimedium herb, 20 parts of donkey-hide gelatin bead and 15 parts of liquorice.
4. A medicament for the treatment of post-chemotherapy bone marrow depression according to claim 1, characterized in that: the material is prepared from the following raw materials in parts by weight: 80 parts of astragalus, 60 parts of angelica, 40 parts of fructus psoraleae, 40 parts of madder, 40 parts of polygonum cuspidatum, 40 parts of curculigo, 50 parts of epimedium, 30 parts of donkey-hide gelatin beads and 20 parts of liquorice.
5. A preparation method of a medicament for treating bone marrow depression after chemotherapy is characterized by comprising the following steps: the method specifically comprises the following steps:
s1: weighing each component and the pharmaceutic adjuvant according to the formula amount of claim 1, wherein the pharmaceutic adjuvant is crushed and then screened, and the other medicinal materials are crushed into coarse powder;
s2: mixing the medicinal materials obtained in the step S1, and decocting the medicinal materials for a plurality of times;
S3: and (3) filtering and combining the decoction obtained in each time of decoction in the step (S2) in sequence to obtain the medicament for treating the bone marrow depression after chemotherapy.
6. The method for preparing the medicine for treating post-chemotherapy bone marrow depression according to claim 5, wherein the method comprises the following steps: the times of decocting the medicinal materials in the step S2 are 3 times, wherein the first time is 3 hours by 12 times of water, the second time is 2 hours by 8 times of water, and the third time is 0.5 hour by 6 times of water.
7. The method for preparing the medicine for treating post-chemotherapy bone marrow depression according to claim 5, wherein the method comprises the following steps: the medicine obtained in the step S3 is one of a soft extract, a capsule, a granule, an oral liquid, a tablet, a pill, a tea, a water decoction or a powder formulation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311778520.0A CN117899159A (en) | 2023-12-22 | 2023-12-22 | Medicine for treating bone marrow depression after chemotherapy and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311778520.0A CN117899159A (en) | 2023-12-22 | 2023-12-22 | Medicine for treating bone marrow depression after chemotherapy and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117899159A true CN117899159A (en) | 2024-04-19 |
Family
ID=90684593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311778520.0A Pending CN117899159A (en) | 2023-12-22 | 2023-12-22 | Medicine for treating bone marrow depression after chemotherapy and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117899159A (en) |
-
2023
- 2023-12-22 CN CN202311778520.0A patent/CN117899159A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103041312B (en) | Traditional Chinese medicine composition with antineoplastic effect and preparation method and application thereof | |
| CN102988821B (en) | Chinese medicine composition for treating carcinomatosis postoperation, postchemotherapy and postradiotherapy and preparation method of Chinese medicine composition | |
| WO2021120972A1 (en) | Traditional chinese medicine composition for treating deficiency of both qi and blood, preparation method therefor and use thereof | |
| CN102772671B (en) | Traditional Chinese medicine composition for treating deficiency of both qi and yin of sicca syndrome | |
| CN102133271B (en) | Medicinal tea for curing gout | |
| CN104083560A (en) | Traditional Chinese medicine for treating cancer related anemia | |
| CN102078511B (en) | Medicine for promoting leukopoiesis | |
| CN101485803B (en) | Chinese medicinal composition for treating menoxenia and dysmenorrhea | |
| CN102526498A (en) | Chinese medicine for eliminating toxic and side effects after nasopharyngeal carcinoma radiotherapy and preparation method and administration way thereof | |
| CN103330868B (en) | Intestinal tract replenishing liquid for chronic renal failure | |
| CN103263587B (en) | Traditional Chinese medicine preparation for treating toxic and side effects of nasopharyngeal carcinoma after radiotherapy and preparation method thereof | |
| CN111544528B (en) | Traditional Chinese medicine composition for treating primary sicca syndrome and application thereof | |
| CN105147996B (en) | Kidney-tonifying marrow-benefiting hematogenesis prescription and preparation method of paste and granules thereof | |
| CN104257883A (en) | Traditional Chinese medicine composition for treating leucopenia after chemotherapy | |
| CN117899159A (en) | Medicine for treating bone marrow depression after chemotherapy and preparation method thereof | |
| CN103341095B (en) | Clysis liquid used for chronic renal failure | |
| CN110934974A (en) | Traditional Chinese medicine composition for treating lung cancer, traditional Chinese medicine preparation and preparation method thereof | |
| CN113082110A (en) | New application of traditional Chinese medicine composition | |
| CN101642485B (en) | Application of medical composition containing astragalus root in preparing medicine for treating leucopenia and Henoch-Schonlein Purpura | |
| CN104587300A (en) | Traditional Chinese medicine composition for treating acute leukemia and preparation method of traditional Chinese medicine composition | |
| CN103768519B (en) | A kind of compound medicine improving cyclophosphamide antitumor curative effect and preparation method thereof | |
| CN102755560B (en) | Traditional Chinese medicine compound reducing chemotherapy side reaction and preparation method and application thereof | |
| CN111514237B (en) | Traditional Chinese medicine composition for treating viral myocarditis and preparation method thereof | |
| CN107137557B (en) | Chinese medicinal compound preparation for treating anemia caused by deficiency of vital energy and essence and preparation method thereof | |
| CN107007721B (en) | Traditional Chinese medicine compound preparation for treating anemia caused by qi deficiency of spleen and kidney and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |